Peer‑reviewed evidence still matters, but it does not close deals Clinical publications continue to anchor credibility, particularly for tools that ...
Transparency rules changed who asks the first question Procurement conversations historically opened with capability and differentiation. Increasingly they open with ...
Hospitals are not rejecting AI. They are staging it. Most large systems now maintain formal digital innovation pathways, pilot programs, ...
A new kind of literacy is spreading through the public: people can read their own physiologic dashboards. They discuss REM ...
Modern medicine relies heavily on material science advancements. New metallurgical blends offer safer, longer-lasting solutions for patients worldwide.
The most dangerous myth about medical artificial intelligence is that the decisive variable is intelligence. The decisive variable is governance: ...
Interoperability used to be discussed as if it were a technical inconvenience, a problem of mismatched formats and outdated interfaces. ...
Clinical medicine often treats cost as a secondary concern, the awkward subject raised after the care plan is already written. ...
Mental health has become a public language. People describe burnout with clinical vocabulary, teenagers narrate anxiety in real time, and ...
The phrase “food as medicine” used to function as a sermon. It was a way of reminding patients to eat ...
Telemedicine is now ordinary, which is precisely why it has become political. Patients schedule video visits with the same casual ...
Need durable medical equipment? Read our top tips on assessing needs, checking insurance, and choosing quality gear for your safety ...
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read moreDaily Remedy offers the best in healthcare information and healthcare editorial content. We take pride in consistently delivering only the highest quality of insight and analysis to ensure our audience is well-informed about current healthcare topics - beyond the traditional headlines.
Daily Remedy website services, content, and products are for informational purposes only. We do not provide medical advice, diagnosis, or treatment. All rights reserved.
© 2026 Daily Remedy
© 2026 Daily Remedy